Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages

Table 3 Network meta-analysis results for annualised relapse rate^a

Drug	SUCRA	GA 20 mg daily	PegIFN β-1a 125 μg every 2 weeks	GA 40 mg thrice weekly	IFN β-1a 44 μg SC thrice weekly	IFN β-1b 250 μg SC every other day	IFN β-1a 22 μg SC thrice weekly	IFN β-1a 30 μg IM weekly	Placebo
GA 20 mg daily	0.77		1.01 (0.77, 1.33)	1.00 (0.80, 1.24)	0.97 (0.85, 1.10)	0.95 (0.86, 1.05)	0.91 (0.76, 1.08)	0.82 (0.73, 0.92)	0.65 (0.59, 0.72)
PegIFN β-1a 125 μg every 2 weeks	0.73			0.98 (0.71, 1.35)	0.95 (0.72, 1.26)	0.94 (0.71, 1.23)	0.89 (0.66, 1.21)	0.81 (0.62, 1.06)	0.64 (0.50, 0.83)
GA 40 mg thrice weekly	0.70				0.97 (0.77, 1.22)	0.96 (0.77, 1.19)	0.91 (0.71, 1.17)	0.82 (0.66, 1.03)	0.66 (0.54, 0.80)
IFN β-1a 44 μg SC thrice weekly	0.64					0.99 (0.86, 1.13)	0.94 (0.80, 1.10)	0.85 (0.76, 0.95)	0.68 (0.60, 0.76)
IFN β-1b 250 μg SC every other day	0.56						0.95 (0.79, 1.14)	0.86 (0.76, 0.97)	0.69 (0.62, 0.76)
IFN β-1a 22 μg SC thrice weekly	0.43							0.91 (0.76, 1.08)	0.72 (0.61, 0.85)
IFN β-1a 30 μg IM weekly	0.18								0.80 (0.72, 0.88)
Placebo	0
Test for inconsistency (χ², df, p)		11.71, 11, 0.38

^aFindings are expressed as rate ratio (RR) with 95% CI
IFN interferon, GA glatiramer acetate, IM intramuscular, SC subcutaneous, SUCRA surface under the cumulative ranking curve

ISSN: 1471-2377